EASD: Low-Dose Aspirin Tied to Lower Risk for New Diabetes in Older Adults

Findings show low-dose aspirin also slows the increase in fasting plasma glucose over time among initially healthy older adults

Adobe Stock

TUESDAY, Sept. 5, 2023 (HealthDay News) -- Aspirin treatment reduces the risk for incident diabetes in older adults, according to a study to be presented at the annual meeting of the European Association for the Study of Diabetes, held from Oct. 2 to 6 in Hamburg, Germany.

Sophia Zoungas, Ph.D., from Monash University in Melbourne, Australia, and colleagues investigated the treatment effect of low-dose aspirin on incident diabetes and fasting plasma glucose (FPG) levels among adults aged 65 years. and older. The participants (16,209 adults) were randomly assigned (1:1) to 100 mg daily enteric-coated aspirin or placebo.

The researchers found that during a median follow-up of 4.7 years, incident diabetes cases were identified in 459 participants in the aspirin group and 536 in the placebo group. The aspirin group had a lower risk for incident diabetes (hazard ratio, 0.85; P = 0.01) and a slower rate of increase in FPG (difference in annual FPG change, −0.006 mmol/L; P = 0.004).

“Given the increasing prevalence of type 2 diabetes among older adults, the potential for anti-inflammatory agents like aspirin to prevent type 2 diabetes or improve glucose levels needs further study,” the authors write.


More Information

Lori Solomon

Lori Solomon

Medically reviewed by Meeta Shah, M.D.

Published on September 05, 2023

Read this Next
About UsOur ProductsCustom SolutionsHow it’s SoldOur ResultsDeliveryContact UsBlogPrivacy PolicyFAQ